(firstQuint)Study of VESIcare In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life.

 Phase 4, multi-center, randomized, double-blind, placebo-controlled, parallel group study.

 All subjects that meet the baseline criteria will be randomized in a 1:1 ratio into VESIcare(R) (solifenacin succinate) or placebo group.

 The study duration consists of a screening period which includes a minimum of a 14 day treatment free wash-out period.

 Subjects meeting the baseline criteria will have a 12 week treatment period.

 Maximum total study duration is 15 weeks: 2 3 week screening / washout period; 12 week double-blind treatment.

 Primary efficacy will be based on OAB-q symptom bother score.

.

 Study of VESIcare In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life@highlight

Evaluate the effect of VESIcare(R) on symptom bother for subjects with OAB